Health TrialsbyHealthPanel

Chronic Myeloid Leukemia - Accelerated Phase

2

Review clinical trials related to Chronic Myeloid Leukemia - Accelerated Phase. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.

Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: Up to 50Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Sep 1, 2026Locations: 4
Eligibility criteria

Age < 22 years of age at the time of diagnosis of malignancy [+32]

Prior myeloablative allogeneic HCT [+28]

Read more
Status: Recruiting

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) prophylaxis will include Cyclophosphamide on Day +3 and +4, tacrolimus, and mycophenolate mofetil.

Participants needed: 38
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: University of Illinois at ChicagoUpdated: Jun 26, 2026Locations: 1
Eligibility criteria

1. Age 18-65 years. [+8]

1a. Left ventricular ejection fraction < 50% [+9]

Read more